Vascular biology of eicosanoids and atherogenesis

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 9, 2009, Pages 1079-1089

  Praticò, Domenico ^a   Dogné, Jean Michel ^b  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF NAMUR   (Belgium)

Author keywords

Atherosclerosis; Cycloxygenase; Eicosanoid; Isoeicosanoid; Isoprostane; Prostacyclin; Receptor; Thromboxane; Thromboxane receptor

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DALTROBAN; G PROTEIN COUPLED RECEPTOR; ICOSANOID; ISOPROSTANE DERIVATIVE; LIPOXYGENASE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN SYNTHASE; PROSTANOID; ROFECOXIB; TERUTROBAN; THROMBOXANE A2; THROMBOXANE SYNTHASE;

AMINO TERMINAL SEQUENCE; ARACHIDONIC ACID METABOLISM; ATHEROGENESIS; ATHEROSCLEROSIS; CARBOXY TERMINAL SEQUENCE; CATALYSIS; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; LIPID PEROXIDATION; LOW DRUG DOSE; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CYCLOOXYGENASE INHIBITORS; DRUG DELIVERY SYSTEMS; EICOSANOIDS; EPOPROSTENOL; HUMANS; INFLAMMATION; ISOPROSTANES; THROMBOXANE A2;

EID: 70450161286     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.91     Document Type: Review

References (83)

1. Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115, E69-E171 (2007). (Pubitemid 46226160)
2. Vakkilainen J, Steiner G, Ansauer JC. Relationships between low density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107, 1733-1737 (2003). (Pubitemid 36418352)
3. Wallace C, Newhouse SJ, Braund P, Zhang F et al. Genome-wide association study indentifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am. J. Hum. Genet. 82, 139-149 (2008). (Pubitemid 351735954)
4. Boudjeltia KZ, Guillaume M, Henuzet C et al. Fibrinolysis and cardiovascular risk factors: association with fibrinogen, lipids, and monocyte count. Eur. J. Inter. Med. 17, 102-108 (2006). (Pubitemid 43265859)
5. Gatto NM, Hodis HN, Liu C-R et al. Brachial artery vasoreactivity is associated with cross-sectional and longitudinal anatomical measures of atherosclerosis in post-menopausal women with coronary artery disease. Atherosclerosis 196, 674-681 (2008).
6. Ingelsson E, Pencina MJ, Tofler GH et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors. The Framingham Offspring Study. Circulation 116, 984-992 (2007). (Pubitemid 47329563)
7. Danesh J, Lewington S, Thompson SG et al.;Fibrinogen Study Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality. An individual participant meta-analysis. JAMA 294, 1799-1809 (2005).
8. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 105, 1135-1143 (2002).
9. Dogne JM, Hanson J, Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol. Sci. 26, 639-644 (2005). (Pubitemid 41636309)
10. Simmons DL, Botting RM, Hla T. Cycloxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56, 387-437 (2004). (Pubitemid 39096597)
11. Smith WL, Garavito RM, de Witt DL. Prostaglandin endoperoxide H synthase (cyclooxygenases)-1 and -2. J. Biol. Chem. 271, 33157-33160 (1996).
12. Chandrasekharan NV, Dai H, Roos L et al. Cox-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc. Natl Acad. Sci. USA 99, 13926-13931 (2002). • First description of the third cyclooxygenase isoform. (Pubitemid 35215482)
13. Kis B, Snipes A, Bari F, Busija DW. Regional distribution of cyclooxygenase-3 mRNA in the rat central nervous system. Brain Res. Mol. Brain Res. 126, 78-80 (2004). (Pubitemid 38781167)
14. Shaftel SS, Olschowka JA, Hurley SD et al. COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells. Brain Res. Mol. Brain Res. 119, 213-215 (2003).
15. Qin N, Zhang SP, Reitz TL et al. Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. J. Pharmacol. Exp. Ther. 315, 1298-1305 (2005). (Pubitemid 41635418)
16. Kis B, Snipes JA, Gaspar T et al. Cloning of cyclooxygenase-1b (putative COX-3) in mouse. Inflamm. Res. 55, 274-278 (2006). (Pubitemid 44359130)
17. Kujubu DA, Fletcher BS, Varnum BC et al. TIS10, a phorbol ester tumor promoterinducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 266, 12866-12872 (1991).
18. Seibert M, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cylcooxygenase 2 in inflammation and pain. Proc. Natl Acad. Sci. USA 91, 12013-12017 (1994). (Pubitemid 24368594)
19. Inoue I, Taba Y, Miwa C et al. Transcriptional and posttranslational regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscl. Thromb. Vasc. Biol. 22, 1415-1420 (2002). (Pubitemid 35050721)
20. Khan KN, Stanfield KM, Harris RK, Baron DA. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren. Fail. 23, 321-330 (2001).
21. Yaksh TL, Dirig DM, Conway CM. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J. Neurosci. 21, 5847-5853 (2001).
22. Dogne JM, de Leval X, Hanson J et al. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr. Med. Chem. 11, 1233-1241 (2004). (Pubitemid 38585063)
23. de Leval X, Hanson J, David LJ et al. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr. Med. Chem. 11, 1243-1252 (2004). (Pubitemid 38585064)
24. Schildknecht S, Ullrich V. Peroxynitrite as regulator of vascular prostanoid synthesis. Arch. Biochem. Biophys. 484, 183-189 (2009). • Comprehensive review on the interaction between nitric oxide and eicosanoid systems.
25. Moncada S, Higgs J, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1, 18-20 (1977). (Pubitemid 8006494)
26. Moncada S, Gryglewski R, Bunting S et al. An enzyme isolated from arteries transform prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263, 663-665 (1976).
27. Praticò D, Dogne J-M. Selective cyclooxygenase-2 inhibitors development in cardiovascular medicine. Circulation 112, 1073-1079 (2005). (Pubitemid 41170276)
28. Cyrus T, Yao Y, Rokach J et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor deficient mice. Circulation 106, 1282-1287 (2002). • First paper showing that biochemical suppression of thromboxane A2 biosynthesis by inducing a potent vascular anti-inflammatory effect reduces atherogenesis and increases plaque stability. (Pubitemid 34988649)
29. Belton O, Byrne D, Kearney D et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102, 840-845 (2000). • Biochemical characterization of prostacyclin formation in human atherosclerosis. (Pubitemid 30671499)
30. Metha J, Roberts A. Human vascular tissues produce thromboxane as well as prostacyclin. Am. J. Physiol. 244, R839-R844 (1983).
31. Katugampola SD, Davenport AP. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1 receptor antagonist losartan. Br. J. Pharmacol. 134, 1385-1392 (2001).
32. 2 receptor blockade suppresses intercellular adhesion molecule-1 expression by stimulated vascular endothelial cells. Eur. J. Pharmacol. 312, 367-377 (1996).
33. Spagnuolo PJ, Ellner JJ, Hassid A, Dunn MJ. Mediation of augmented monocyte adhesiveness by thromboxane. Inflammation 12, 1-9 (1988). (Pubitemid 18065884)
34. Tzoulaki I, Murray GD, Lee AJ et al. C-reactive protein, interleukin-6, and soluble adhesion molecules predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 112, 976-983 (2005). (Pubitemid 41170265)
35. Bayat H, Xu S, Pimentel D, Cohen RA, Jiang B. Activation of thromboxane receptor upregulates interleukin (IL) -1β-induced VCAM-1 expression through JNK signal. Arterioscl. Thromb. Vasc. Biol. 28, 127-134 (2008).
36. 2 receptor expression by lipid soluble smoking particles through post-transcriptional mechanisms. Atherosclerosis 196, 608-616 (2008).
37. Bailey JM, Butter J. Anti-inflammatory drugs in experimental atherosclerosis. I. Relative potencies for inhibiting plaque formation. Atherosclerosis 17, 515-522 (1973).
38. Paul A, Calleja L, Camps J et al. The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci. 68, 457-465 (2000). (Pubitemid 32011897)
39. Praticò D, Tillmann C, Zhang ZB et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor-knockout mice. Proc. Natl Acad. Sci. USA 98, 3358-3363 (2001). •• In vivo pharmacological evidence that COX-1-dependent thromboxane biosynthesis plays a functional role in experimental atherogenesis.
40. Belton O, Duffy A, Toomey S, Fitzgerald DJ. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E-knockout mouse model of atherosclerosis. Circulation 108, 3017-3023 (2003). (Pubitemid 37553572)
41. Antithrombotic Trialists 'Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 324, 71-86 (2002).
42. Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352, 1293-1304 (2005).
43. Metz J, Wolf O, Schmelz A, Pill J, Stegmeier KH, Hartig F. Atherosclerosis in the aorta of hypercholesterolemic rabbits and the influence of daltroban. Exp. Pathol. 41, 57-69 (1991).
44. Cayatte AJ, Du Y, Olivier-Krazinski J et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apoE-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscl. Thromb. Vasc. Biol. 20, 1724-1728 (2000). • Biological evidence that in a mouse model, pharmacological blockade of the thromboxane receptor significantly reduces atherogenesis. (Pubitemid 30470586)
45. Viles-Gonzales JF, Fuster V, Corti R et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition - a magnetic resonance imaging study. Eur. Heart J. 26, 1557-1561 (2005). (Pubitemid 41373499)
46. Worth NF, Berry CL, Thomas AC, Campbell JH. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 183, 65-73 (2005).
47. Vilahur G, Casani L, Badimon L. A thromboxane A2/prostgalndin H2-receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb. Haemost. 98, 662-669 (2007). (Pubitemid 47412894)
48. Cyrus T, Yao Y, Ding T, Dogne JM, Pratico D. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. Eur. J. Pharmacol. 561, 105-111 (2007). (Pubitemid 46437399)
49. 2-isoprosyane levels), that is, atherosclerosis, blockade of the thromboxane receptor together with suppression of its biosynthesis affords a greater therapeutic effect.
50. Praticò D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 96, 3823-3826 (2000). • Biochemical evidence from two distinct mouse models of atherosclerosis that, similar to human atherosclerosis, the eicosanoid system is altered.
51. Dogne JM, Hanson J, Supuran C, Praticó D. Coxibs and cardiovascular side-effects: from light to shadow. Curr. Pharm. Des. 12, 971-975 (2006).
52. Cheng Y, Wang M, Yu Y et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest. 116, 1391-1399 (2006).
53. Hennan JK, Huamng J, Barret TD et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104, 820-825 (2001).
54. Zewde T, Mattson, DL. Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension 44, 424-428 (2004). (Pubitemid 39281490)
55. Pidgeon GP, Tamosiuniene R, Chen G et al. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation 110, 2701-2707 (2004). (Pubitemid 39453022)
56. Murata T, Ushikubi F, Matsuoka T et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388, 678-682 (1997). (Pubitemid 27366439)
57. Burleigh ME, Babaev VR, Oates JA et al. Cycloxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105, 1816-1823 (2002).
58. Rott D, Zhu J, Burnett MS et al. Effects of MF-tricyclic, a selective cycloxygenase-2 inhibitor, on atherogenesis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E-knockout mice. J. Am. Coll. Cardiol. 41, 1812-1819 (2003).
59. Bea F, Blessing E, Bennett BJ et al. Chronic inhibition of cycloxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc. Res. 60, 198-204 (2003). (Pubitemid 38373492)
60. Olensen M, Kwong E, Meztli A et al. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand. Cardiovasc. J. 36, 362-367 (2002). (Pubitemid 36131423)
61. Metzner J, Popp L, Marian C et al. The effects of COX-2 selective and nonselective NSAIDs on the initiation and progression of atherosclerosis in apoE-/-mice. J. Mol. Med. 85, 623-633 (2007). (Pubitemid 46870892)
62. 2-Isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 147, 1-10 (1999).
63. Pratico D, Lawson JA, Rokach J et al. The isoprostanes in biology and medicine. Trends Endocrinol. Metab. 12, 243-247 (2001).
64. 2α by human monocytes: discriminant production by reactive oxygen species and PG G/H S-2. J. Biol. Chem. 271, 8919-8924 (1996).
65. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Circulation 105, 2107-2111 (2002).
66. Witztum JL, Berliner JA. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr. Op. Lipid. 9, 441-448 (1998).
67. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005).
68. 2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100, 2028-2034 (1997). • First biochemical and immunohistochemical evidence that isoeicosanoids are present in human aortic atherosclerotic lesions.
69. Pratico D. Lipid peroxidation in mouse models of atherosclerosis. Trends Cardiovasc. Med. 11, 112-116 (2001). (Pubitemid 33070333)
70. 2-α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99, 224-229 (1999).
71. 2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J. Am. Coll. Cardiol. 37, 76-80 (2001).
72. 2-isoprostanes to plaque instability in human carotid atherosclerosis. J. Clin. Invest. 103, 421-427 (1999). • Evidence that enzyme-derived and nonenzymatic derived eicosanoids are modulators of in vivo plaque phenotype.
73. Praticò D, Tangirala R, Rader DJ et al. Vitamin E suppresses isoprostanes generation in vivo and reduces atherogenesis in ApoE-deficient mice. Nature Med. 4, 1189-1192 (1998). • Demonstrates that suppression of isoeicosanoid formation results in a significant reduction of atherogenesis. (Pubitemid 28468835)
74. Cyrus T, Yao Y, Rokach J et al. Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-deficient mice with established vascular lesions. Circulation 107, 521-523 (2003). (Pubitemid 36176798)
75. Terasawa Y, Ladha Z, Leonard SW et al. Increased atherosclerosis in hyperlipidemic mice deficient in a-tocopherol transfer protein and vitamin E. Proc. Natl Acad. Sci. USA 97, 13830-13834 (2000).
76. 2-isoprostanes are not only biomarkers of oxidative stress in vivo, but also an independent cardiovascular risk marker for future cardiovascular events.
77. 2-isoprostanes are not just markers of oxidative stress. Free Rad. Biol. Med. 44, 247-256 (2008).
78. 2α. J. Biol. Chem. 271, 14916-14924 (1996).
79. 2α-III. Evidence from apolipoprotein E- and LDL receptor-deficient mice. Circulation 112, 2867-2874 (2005). •• Biological evidence that the thromboxane receptor is the biological link between high levels of isoeicosanoid and atherogenesis via an upregulation of the vascular inflammatory responses.
80. 2 biosynthesis alone does not afford the best therapeutic protection in patients with coronary artery disease.
81. Shih DM, Xia YR, Wang XP et al. Combined serum paroxonase-knockout/ apolipoprotein E-knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275, 17527-115735 (2000).
82. Cyrus T, Witztum JL, Rader DJ et al. Disruption of 12/15LO-lipoxygenase gene diminishes atherosclerosis in apoE-deficient mice. J. Clin. Invest. 103, 1597-1604 (1999). • First in vivo demonstration of an active role of 12/15 lipoxygenase in atherogenesis.
83. Tang L, Ding T, Pratico D. Additive anti-atherogenic effect of thromboxane receptor antagonism with 12/15 lipoxygenase gene disruption in apolipoprotein E deficient mice. Atherosclerosis 199, 265-270 (2008).